Investment Thesis

Viatris Inc. (VTRS) is a BUY at the current price of $16.20, driven by a strong portfolio of established pharmaceutical products coupled with an expanding biosimilars segment which positions the company favorably within a growing global healthcare market. Despite its recent struggles with profitability metrics, the market is underestimating the potential for revenue recovery and growth in emerging markets and biosimilars, which could lead to significant upside over the next 12-24 months.

Competitive Moat

Viatris possesses a competitive moat characterized by significant intangible assets, including a diverse portfolio of well-known branded medications and established generic products. The company's scale provides economies of scale in production and distribution, allowing for competitive pricing and enhanced negotiation power with healthcare providers. However, threats from generic competition and regulatory challenges in various jurisdictions may weaken this moat over time, particularly in the face of increasing biosimilar entrants from rivals like Amgen and Sandoz.

Growth Engine

Future revenue growth for Viatris is anticipated to stem primarily from the expansion of its biosimilar portfolio and increased penetration in emerging markets, where demand for affordable medications is accelerating. The total addressable market for biosimilars is projected to reach $100 billion by 2025, with Viatris positioned to capture a significant share through its established products like SEMGLEE and Ogivri. Geographically, the company is focusing on enhancing its presence in China and other high-growth regions, while also leveraging its existing portfolio to drive organic growth rather than relying solely on acquisitions.